Kosmonova buran
Top-News
Tickertafel ZENOSENSE
Beiträge: 24
Zugriffe: 5.011 / Heute: 1
Zugriffe: 5.011 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +71,71%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +52,30%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +38,10%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +36,22%
Zeit Kurs Stück
20:55:24§0,09 $ 400
20:54:35§0,09 $ 4.000
18:02:17§0,09 $ 500
15:30:50§0,09 $ 2.600
15:30:04§0,10 $ 1.000
_____________________
GRATULATION
20:55:24§0,09 $ 400
20:54:35§0,09 $ 4.000
18:02:17§0,09 $ 500
15:30:50§0,09 $ 2.600
15:30:04§0,10 $ 1.000
_____________________
GRATULATION
Datum Erster Hoch Tief Schluss Stücke Volumen
25.06.15 0,10 0,10§0,0826 0,0903 $ 66.393 6.304
GrB
25.06.15 0,10 0,10§0,0826 0,0903 $ 66.393 6.304
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
26.06.15 0,0856 0,10§0,07 0,082 $ 100.634 7.896
GrB
26.06.15 0,0856 0,10§0,07 0,082 $ 100.634 7.896
GrB
:::::::::::::::: 0,0806 $ +0,75% +0,0006 $
In Euro: 0,0726 € | Nasdaq OTC Other, 02.07.15 ,GrB
In Euro: 0,0726 € | Nasdaq OTC Other, 02.07.15 ,GrB
:::::::::::::: 0,09 $ +12,36% +0,0099 $
In Euro: 0,0820 € | Nasdaq OTC Other, 24.07.15 ,GrB
In Euro: 0,0820 € | Nasdaq OTC Other, 24.07.15 ,GrB
:::::::::::::: 0,0775 $ +10,71% +0,0075 $
In Euro: 0,0699 € | Nasdaq OTC Other, 14.08.15 ,GrB
In Euro: 0,0699 € | Nasdaq OTC Other, 14.08.15 ,GrB
Corporate Name: Zenosense, Inc
Exchange/Symbol:§ZENO
Shares Issued and Outstanding: 48,461,741
Shares Authorized: 500,000,000
CUSIP #: 989424 106
ISIN#:§US9894241069
Fiscal Year End: December 31
Date of Incorporation: August 2008
Incorporated:§Nevada, USA
Transfer Agent: Holladay Stock Transfer
Corporate Attorneys: Goldenbock Eiseman Assor Bell & Peskoe
437 Madison Avenue- 40th Floor
New York, New York 10022
Auditors:§GBH CPA’s
zenosense.net/investors/zeno-snap-shot/
Exchange/Symbol:§ZENO
Shares Issued and Outstanding: 48,461,741
Shares Authorized: 500,000,000
CUSIP #: 989424 106
ISIN#:§US9894241069
Fiscal Year End: December 31
Date of Incorporation: August 2008
Incorporated:§Nevada, USA
Transfer Agent: Holladay Stock Transfer
Corporate Attorneys: Goldenbock Eiseman Assor Bell & Peskoe
437 Madison Avenue- 40th Floor
New York, New York 10022
Auditors:§GBH CPA’s
zenosense.net/investors/zeno-snap-shot/
global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Two devices are currently under development; a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA); and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness. zenosense.net/
natural processes: By example, highly trained dogs have been able to recognize prostate cancer-specific VOCs and detect prostate cancer in urine samples with 98% accuracy. While humans have roughly five million olfactory cells in their noses, dogs have about 200 million. This natural, learned detection by multiple sensors is analogous to the Zenosense technology platform which, by clever electronic processing, effectively utilizes an infinite number of sensors and software that “learns” to recognize the relevant VOCs.
zenosense.net/
zenosense.net/
experts in nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry. Collaborations and partnerships are also in place with hospitals, universities and a private laboratory in the fields of sensors, polymer electrochemistry, microbiology, infectious disease, pneumology, chromatography and microorganism identification. zenosense.net/
buran & MARIO www.facebook.com/mario.meierhof
buran & MARIO www.facebook.com/mario.meierhof
Datum Erster Hoch Tief Schluss Stücke Volumen
27.01.16 0,024 0,0244§0,024 0,024 $ 2.913 70
GrB
27.01.16 0,024 0,0244§0,024 0,024 $ 2.913 70
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
22.04.16 0,02 0,02§0,02 0,02 $ 200 4
GrB
22.04.16 0,02 0,02§0,02 0,02 $ 200 4
GrB
Handelsplatz Letzter Änderung Vortag letzte Stk. Tag-Stk. Kurspanne Zeit
Nasdaq OTC Other 0,1939 $ -11,86% 0,22 $ 110 110 0,1939 - 0,1939 02.11.16
GrB
Nasdaq OTC Other 0,1939 $ -11,86% 0,22 $ 110 110 0,1939 - 0,1939 02.11.16
GrB
thats what I found...
ZenoSense (OTC ZENO) is rapidly becoming a major player in the medical device field, and experts are saying it is set to virtually explode onto the scene.
ZenoSense (OTC ZENO) is a company which combines industry-leading talent and stringent standards to measure success. The medical device industry took a major credibility hit with the revelations that Theranos may have mislead investors and hyped up their technology in order to grow and roll out their services. While this has been seen as a negative for the industry, ZenoSense has found a major opportunity, leading to some stunning potential upsets in the practice of using new technology to replace standard laboratory testing.
The medical device industry has always been one of the more profitable industries in the country. Combining the testing standards of pharmaceuticals, but not requiring the hundreds of millions of dollars necessary to succeed with the FDA, the profits generated by solid technology and corporate transparency have yielded amazing returns. ZenoSense (OTC ZENO) makes sure to adhere to both principles as its core philosophy. While most medical technology companies go public only as a way to help investors feel more comfortable with the liquidity of their investment, ZenoSense does it in order to be able to adhere to the rigid standards of the SEC right from the beginning. It is more than faith in the technology, it is faith in the company as a whole -- with a transparent mission, ZenoSense offers an opportunity that its investors can feel comfortable with, and innovative technology that is changing the industry.
There have been more than a few companies that have ventured into the field of testing technology, but few have received the results ZenoSense (OTC ZENO) has in such a short period of time. The core focus of ZenoSense has been through a joint venture with MIDS Medical focusing on a product called MIDS Cardiac™. A handheld device which is being developed to provide rapid testing of cardiac markers for use at the Point of Care, MIDS Cardiac could give doctors the ability to provide their patients with diagnostic results equal or superior to laboratory tests. This not only allows the results to be able to aide in treatment almost in real time, but allows patients to avoid the deadly delays that even a day of waiting can cause. ZenoSense can confidently say that MIDS Cardiac™ can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI), a major cardiac condition.
ZenoSense (OTC ZENO) isn't just tearing up the markets, but the industry as a whole as well. The medical device industry, as measured by the Dow Jones Medical Equipment Index, with combined sales in the trillions of dollars, has consistently provided returns to investors above 10% annually since it began being measured. It has solidly outperformed the S&P Index in every year it was measured since the index's inception in 2006.
To see the opportunity provided by ZenoSense (OTC ZENO), all one has to do is dive even further into the industry. According to a 2015 report sponsored by the American Heart Association, 85.6 million people suffer from cardiac diseases in the United States alone. With the population aging and the Baby Boomer generation retiring, the growth in obesity rates and other factors is only going to increase. Experts have also cautioned that with the addition of more than 20 million people to the health insurance rolls since the rollout of the Affordable Care Act, there is also a further strain on the amount of doctors and laboratory services available. The medical device industry has been there consistently to pick up the slack, by shortening the time period between testing and diagnosis, reducing costs and providing better outcomes to the public.
Additionally, there's a fear that the tax on the industry from the Affordable Care Act would stifle innovation and reduce the ability of the industry to grow as it has. In a sign of stunning bipartisanship, both parties in the United States passed a suspension of that tax for two years in 2015. There is talk about the tax facing certain repeal under the current administration, but even if it comes back, it is a stronger incentive to get into the industry now as there is still more than a year left before it is slated to return.
ZenoSense (OTC ZENO) has also made sure to use its current resources to ensure that its MIDS Medical team is made up of some of the best and brightest staff in the world. With more than thirty years' experience in magnetic measurement and sensor design, and a focus on nanoparticle applications and the highest industry experts in micro-magnetic and luminescence techniques, it stands alone at the top of the field. Strengthening the team even further is recent news of a contract to work with Future Diagnostics who have developed assays for several of the world's largest multi-national diagnostic companies and highly specialist in modern cardiac assays.
ZenoSense (OTC ZENO) is rapidly becoming a major player in the medical device field, and experts are saying it is set to virtually explode onto the scene.
ZenoSense (OTC ZENO) is a company which combines industry-leading talent and stringent standards to measure success. The medical device industry took a major credibility hit with the revelations that Theranos may have mislead investors and hyped up their technology in order to grow and roll out their services. While this has been seen as a negative for the industry, ZenoSense has found a major opportunity, leading to some stunning potential upsets in the practice of using new technology to replace standard laboratory testing.
The medical device industry has always been one of the more profitable industries in the country. Combining the testing standards of pharmaceuticals, but not requiring the hundreds of millions of dollars necessary to succeed with the FDA, the profits generated by solid technology and corporate transparency have yielded amazing returns. ZenoSense (OTC ZENO) makes sure to adhere to both principles as its core philosophy. While most medical technology companies go public only as a way to help investors feel more comfortable with the liquidity of their investment, ZenoSense does it in order to be able to adhere to the rigid standards of the SEC right from the beginning. It is more than faith in the technology, it is faith in the company as a whole -- with a transparent mission, ZenoSense offers an opportunity that its investors can feel comfortable with, and innovative technology that is changing the industry.
There have been more than a few companies that have ventured into the field of testing technology, but few have received the results ZenoSense (OTC ZENO) has in such a short period of time. The core focus of ZenoSense has been through a joint venture with MIDS Medical focusing on a product called MIDS Cardiac™. A handheld device which is being developed to provide rapid testing of cardiac markers for use at the Point of Care, MIDS Cardiac could give doctors the ability to provide their patients with diagnostic results equal or superior to laboratory tests. This not only allows the results to be able to aide in treatment almost in real time, but allows patients to avoid the deadly delays that even a day of waiting can cause. ZenoSense can confidently say that MIDS Cardiac™ can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI), a major cardiac condition.
ZenoSense (OTC ZENO) isn't just tearing up the markets, but the industry as a whole as well. The medical device industry, as measured by the Dow Jones Medical Equipment Index, with combined sales in the trillions of dollars, has consistently provided returns to investors above 10% annually since it began being measured. It has solidly outperformed the S&P Index in every year it was measured since the index's inception in 2006.
To see the opportunity provided by ZenoSense (OTC ZENO), all one has to do is dive even further into the industry. According to a 2015 report sponsored by the American Heart Association, 85.6 million people suffer from cardiac diseases in the United States alone. With the population aging and the Baby Boomer generation retiring, the growth in obesity rates and other factors is only going to increase. Experts have also cautioned that with the addition of more than 20 million people to the health insurance rolls since the rollout of the Affordable Care Act, there is also a further strain on the amount of doctors and laboratory services available. The medical device industry has been there consistently to pick up the slack, by shortening the time period between testing and diagnosis, reducing costs and providing better outcomes to the public.
Additionally, there's a fear that the tax on the industry from the Affordable Care Act would stifle innovation and reduce the ability of the industry to grow as it has. In a sign of stunning bipartisanship, both parties in the United States passed a suspension of that tax for two years in 2015. There is talk about the tax facing certain repeal under the current administration, but even if it comes back, it is a stronger incentive to get into the industry now as there is still more than a year left before it is slated to return.
ZenoSense (OTC ZENO) has also made sure to use its current resources to ensure that its MIDS Medical team is made up of some of the best and brightest staff in the world. With more than thirty years' experience in magnetic measurement and sensor design, and a focus on nanoparticle applications and the highest industry experts in micro-magnetic and luminescence techniques, it stands alone at the top of the field. Strengthening the team even further is recent news of a contract to work with Future Diagnostics who have developed assays for several of the world's largest multi-national diagnostic companies and highly specialist in modern cardiac assays.
and here some news:
www.4-traders.com/ZENOSENSE-INC-15046793/...ATIONS-f-24218796/
www.4-traders.com/ZENOSENSE-INC-15046793/...ATIONS-f-24218796/
VALENCIA, SPAIN--(Marketwired - Jun 15, 2017) - Zenosense, Inc. ( OTC PINK : ZENO ) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that its MIDS Medical Limited joint venture ("MML") based at Sci-Tech, Daresbury (UK), has received notice of a patent issuance in the U.S.
Our joint venture partner in MML has received a United States Patent and Trademark Office grant for the issuance of the central MIDS patent under number 9,678,064 in the U.S., namely: "Immunoassay Apparatus Incorporating Microfluidic Channel".
This is as a result of a patent application originally filed in 2011 by our MML joint venture partner. It is one of a number of applications made in commercially crucial regions for patent protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other applications have also successfully progressed into the national phase in the EU and India. This issuance in the U.S. indicates that these latter territories are also likely to progress to grant and, if so, will establish intellectual property protection in these key commercial regions. The MIDS patents are under license for the exclusive use by MML and will be transferred directly to MML in the event of the conclusion of a relevant commercial deal with a third party.
Carlos Gil, CEO of Zenosense Inc., commented: "This latest grant of the MIDS patent in the U.S. further validates our confidence in the ability of the MML team to deliver this exciting technology. I also expect to be able to provide a further update on development activities in the coming weeks."
Our joint venture partner in MML has received a United States Patent and Trademark Office grant for the issuance of the central MIDS patent under number 9,678,064 in the U.S., namely: "Immunoassay Apparatus Incorporating Microfluidic Channel".
This is as a result of a patent application originally filed in 2011 by our MML joint venture partner. It is one of a number of applications made in commercially crucial regions for patent protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other applications have also successfully progressed into the national phase in the EU and India. This issuance in the U.S. indicates that these latter territories are also likely to progress to grant and, if so, will establish intellectual property protection in these key commercial regions. The MIDS patents are under license for the exclusive use by MML and will be transferred directly to MML in the event of the conclusion of a relevant commercial deal with a third party.
Carlos Gil, CEO of Zenosense Inc., commented: "This latest grant of the MIDS patent in the U.S. further validates our confidence in the ability of the MML team to deliver this exciting technology. I also expect to be able to provide a further update on development activities in the coming weeks."
VALENCIA, SPAIN--(Marketwired - Jun 15, 2017) - Zenosense, Inc. ( OTC PINK : ZENO ) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that its MIDS Medical Limited joint venture ("MML") based at Sci-Tech, Daresbury (UK), has received notice of a patent issuance in the U.S.
Our joint venture partner in MML has received a United States Patent and Trademark Office grant for the issuance of the central MIDS patent under number 9,678,064 in the U.S., namely: "Immunoassay Apparatus Incorporating Microfluidic Channel".
This is as a result of a patent application originally filed in 2011 by our MML joint venture partner. It is one of a number of applications made in commercially crucial regions for patent protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other applications have also successfully progressed into the national phase in the EU and India. This issuance in the U.S. indicates that these latter territories are also likely to progress to grant and, if so, will establish intellectual property protection in these key commercial regions. The MIDS patents are under license for the exclusive use by MML and will be transferred directly to MML in the event of the conclusion of a relevant commercial deal with a third party.
Carlos Gil, CEO of Zenosense Inc., commented: "This latest grant of the MIDS patent in the U.S. further validates our confidence in the ability of the MML team to deliver this exciting technology. I also expect to be able to provide a further update on development activities in the coming weeks."
Our joint venture partner in MML has received a United States Patent and Trademark Office grant for the issuance of the central MIDS patent under number 9,678,064 in the U.S., namely: "Immunoassay Apparatus Incorporating Microfluidic Channel".
This is as a result of a patent application originally filed in 2011 by our MML joint venture partner. It is one of a number of applications made in commercially crucial regions for patent protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other applications have also successfully progressed into the national phase in the EU and India. This issuance in the U.S. indicates that these latter territories are also likely to progress to grant and, if so, will establish intellectual property protection in these key commercial regions. The MIDS patents are under license for the exclusive use by MML and will be transferred directly to MML in the event of the conclusion of a relevant commercial deal with a third party.
Carlos Gil, CEO of Zenosense Inc., commented: "This latest grant of the MIDS patent in the U.S. further validates our confidence in the ability of the MML team to deliver this exciting technology. I also expect to be able to provide a further update on development activities in the coming weeks."
..klick klick klick www.zenosense.com/ GrB
Neueste Beiträge aus dem ZENOSENSE, INC. Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 23 | Tickertafel ZENOSENSE | buran | buran | 25.04.21 13:04 |
